Skip to main content

Tagged With "Chronic idiopathic urticaria"

Blog Post

AAFA Urges Inclusion of Patient Voice in Analysis of Costly New Asthma Drugs

AAFA Community Services ·
Biologics are a new class of drugs that fight disease at the source . Instead of attacking symptoms, these drugs target diseases like asthma at a molecular level. These newer types of drugs are more expensive than older medicines. That is prompting public discussion on how to pay for them. The cost of caring for patients with the most severe forms of asthma represents a majority of asthma healthcare spending. In addition, asthma is a leading cause of missed time from work and school. Last...
Blog Post

Asthma and Allergy Research Review, April-June 2017

AAFA Community Services ·
The Asthma and Allergy Foundation of America will recap some of the top research on allergies and asthma every quarter. Here is a look at studies reported between April and June 2017. Learn why some children may not respond to asthma treatments, how testosterone may affect asthma and more.
Blog Post

Hives That Won’t Go Away: The Basics of CIU

AAFA Community Services ·
Hives, those annoying itchy red bumps, often occur with an allergic reaction or sometimes a viral infection. Or sometimes, they can be more serious when they happen with a severe allergic reaction called anaphylaxis.
Blog Post

FDA Approves Symbicort to Treat Asthma In Children Ages 6-12

AAFA Community Services ·
AstraZeneca announced that the US Food and Drug Administration (FDA) approved SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol 80/4.5 micrograms for the treatment of asthma in pediatric patients aged six up to 12 years.
Blog Post

FDA Approves Two New Asthma Inhalers

AAFA Community Services ·
[Press Release] Teva Announces FDA Approval of Two New RespiClick® Maintenance Inhalers for the Treatment of Asthma Approvals Expand Portfolio of Respiratory Medicines Delivered in RespiClick® Inhaler Designed to Eliminate the Need for Hand-Breath Coordination During Inhalation JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Administration (FDA) approved two products for adolescent and adult patients with asthma.
Blog Post

FDA Will Consider Xolair for the Treatment of Nasal Polyps

AAFA Community Services ·
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to intranasal corticosteroids.
Blog Post

GlaxoSmithKline Study Shows Nucala Improves Quality of Life, Lung Function in Severe Asthma

AAFA Community Services ·
GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data demonstrating that severe asthma patients, whose disease is driven by eosinophilic inflammation, treated with first-in-class biologic Nucala® (mepolizumab) added-on to standard of care, achieved clinically and statistically significant improvements in their health-related quality of life and lung function, when compared to patients treated with placebo and standard of care. These results are from the phase IIIb MUSCA study (NCT02281318, 200
Blog Post

Health Care Rule That Could Affect Those With Chronic Conditions Is Finalized

AAFA Community Services ·
The Trump Administration released a final rule expanding the scope and applicability of association health plans (AHPs). The Department of Labor’s rule implements President Trump’s October 2017 executive order which directed agencies to change existing regulations to provide consumers with more options for health care coverage.
Blog Post

Teva Announces FDA Approval of QVAR® RediHaler™ Inhaler

AAFA Community Services ·
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved QVAR® RediHaler™ (beclomethasone dipropionate HFA) inhalation aerosol, a breath-actuated inhaler for the maintenance treatment of asthma as a prophylactic therapy in patients 4 years of age and older.
Blog Post

Teva Launches AirDuo™ RespiClick® and its Authorized Generic

AAFA Community Services ·
[Press Release] Teva Launches AirDuo™ RespiClick® and its Authorized Generic, Two Inhalers Containing Fluticasone Propionate and Salmeterol First and Only Generic Fluticasone Propionate and Salmeterol (ICS/LABA) Inhaler Available in the U.S. JERUSALEM, April 20, 2017 – Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the simultaneous launch of AirDuo™ RespiClick® (fluticasone propionate and salmeterol) inhalation powder and its authorized generic for the treatment...
Blog Post

World Allergy Week Highlights the Agony of Chronic Hives

AAFA Community Services ·
Do you suffer from hives? This week marks World Allergy Week, and the theme for this year’s event is The Agony of Hives - What to do when welts and swelling do not go away. The medical name for hives is urticaria. Hives are a common sign of an allergic reaction. Hives can also occur due to other causes, including a viral infection. Learn more by visiting Hives (Urticaria) . Find out when to call your health care provider, and when to go to the emergency room or call 911. Hives can occur due...
Blog Post

LUSTER Clinical Trial Results for People With Uncontrolled Moderate-to-Severe Asthma Announced

AAFA Community Services ·
Novartis today announced topline results from its pivotal global Phase III LUSTER-11 and LUSTER-22 studies exploring the efficacy and safety of the investigational oral, once-daily, DP2 receptor antagonist fevipiprant (QAW039). The pooled analyses of the LUSTER trials did not meet3 the clinically relevant threshold for reduction in rate of moderate-to-severe exacerbation compared to placebo over a 52-week treatment period for either of the doses (150mg / 450 mg).
Comment

Re: Blowing Asthma right out of the park!

Kathy P ·
Awesome! Both of my kids played wind instruments (trumpet and bass clarinet). It seemed to help with their asthma. Is he in a marching band? My kids were and would have issues with evening shows being outside all day.
Comment

Re: Blowing Asthma right out of the park!

Melissa G ·
That's great! Thanks for sharing! There is currently a discussion about What do you say when you tell them you have asthma or allergies? on the forums. What ideas would you share with other members?
Comment

Re: Health Care Rule That Could Affect Those With Chronic Conditions Is Finalized

Amber Says Shine ·
Thanks for this info. Are there any recommended action items if we'd like to get involved? Recommendations for calling/writing our Congressional Representatives, for example.
Comment

Re: Health Care Rule That Could Affect Those With Chronic Conditions Is Finalized

Kathy P ·
Amber - we are working behind the scenes and will let everyone know about actions to take once things are finalized. Stay tuned!
Comment

Re: Health Care Rule That Could Affect Those With Chronic Conditions Is Finalized

Melanie Carver ·
If you receive health insurance through your job, be sure to tell your employer now how important affordable, non-discriminatory health care is to you and your family! Many employers are shopping around for plans now before open enrollment begins in late fall.
Blog Post

Asthma and Allergy Research With You as an Equal Partner

AAFA Community Services ·
The Asthma and Allergy Foundation of America (AAFA) conducts and promotes patient-centered research to help you. This means your beliefs, preferences and needs are at the center of our research. Your input drives our advocacy work, guides our education programs and supports our community. Recently, we’ve studied the following topics: Symptoms of anaphylaxis in infants and toddlers Eczema burdens and people’s experiences with treatments Impact of COVID-19 on people with asthma and allergy Air...
Blog Post

FDA Approves Dupixent® (Dupilumab) for Children Aged 6 to 11 Years With Moderate-to-Severe Atopic Dermatitis

AAFA Community Services ·
The U.S. Food and Drug Administration (FDA) approved Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent is the only biologic medicine approved for this patient population.
Blog Post

FDA Accepts Biologics License Application for Xolair® Prefilled Syringe for Self-Administration

AAFA Community Services ·
Novartis today announced that the US Food and Drug Administration (FDA) accepted the company's supplemental Biologics License Application (sBLA) for a new self-administration option for Xolair® (omalizumab) across all approved US indications. If approved, Xolair prefilled syringe would become available for either self-administration by select patients or administration by their caregivers.
Blog Post

The Power of Your Gift: Improving Lives Through Asthma and Allergy Research

AAFA Community Services ·
When Diana Hanley’s daughter Jamie was a baby, she wheezed every time she got sick. She had her first allergic reaction to eggs at 11 months. Around age 2, she was diagnosed with a peanut allergy. And because of constant hives, many foods were removed from her diet. Her family is now part of research to help families managing asthma and allergies. Read Jamie's story.
Blog Post

FDA Approves Xolair® (Omalizumab) Prefilled Syringe for Self-Injection

AAFA Community Services ·
Novartis today announced that the US Food and Drug Administration (FDA) approved the supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection in appropriate patients across all approved US indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic idiopathic urticaria (CIU) and nasal polyps.
Blog Post

Dupixent® (Dupilumab) Improves Lung Function and Reduces Asthma Attacks in Children in Phase 3 of Clinical Trial

AAFA Community Services ·
The Asthma and Allergy Foundation of America (AAFA) is sharing this press release to bring you the latest research news quickly. [PRESS RELEASE] Pivotal Data at ATS 2021 Show Dupixent® (dupilumab) Significantly Reduced Asthma Attacks and Improved Lung Function in Children Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma in a randomized Phase 3 trial, with potential to be best-in-class treatment for...
×
×
×
×